首页 > 最新文献

中华预防医学杂志最新文献

英文 中文
[Expert consensus on the passive immunization prevention of infant respiratory syncytial virus infection in China]. [中国婴儿呼吸道合胞病毒感染被动免疫预防专家共识]。
Q3 Medicine Pub Date : 2024-10-08 DOI: 10.3760/cma.j.cn112150-20240826-00684

Respiratory syncytial virus (RSV) infection, which has the very heavy disease burdens, is the most common viral pathogen that seriously threatens the health of infants and young children. In order to better guide and standardize the clinical diagnosis, treatment, monitoring and immunization prevention and control of RSV infection in China, the Chinese Preventive Medicine Association jointly organized multidisciplinary experts to form a special working group, drawing on the implementation experience of foreign passive immunization prevention of RSV, integrating the existing evidence and the latest progress as a problem oriented, and putting forward the expert consensus on the passive immunization prevention of infant RSV infection in China in the future. The aim is to answer some professional questions about RSV infection and its immunoprophylaxis, especially passive immunoprophylaxis, in order to provide reference for the practice of immunoprophylaxis for professionals in medical institutions, disease prevention and control institutions and community health service centers at all levels.

呼吸道合胞病毒(RSV)感染疾病负担极重,是严重威胁婴幼儿健康的最常见病毒性病原体。为了更好地指导和规范我国RSV感染的临床诊断、治疗、监测和免疫防控工作,中华预防医学会联合多学科专家组成专项工作组,借鉴国外RSV被动免疫预防的实施经验,以问题为导向,整合现有证据和最新进展,提出了未来我国婴幼儿RSV感染被动免疫预防的专家共识。旨在解答有关RSV感染及其免疫预防,尤其是被动免疫预防的一些专业问题,为各级医疗机构、疾病预防控制机构和社区卫生服务中心的专业人员提供免疫预防的实践参考。
{"title":"[Expert consensus on the passive immunization prevention of infant respiratory syncytial virus infection in China].","authors":"","doi":"10.3760/cma.j.cn112150-20240826-00684","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240826-00684","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) infection, which has the very heavy disease burdens, is the most common viral pathogen that seriously threatens the health of infants and young children. In order to better guide and standardize the clinical diagnosis, treatment, monitoring and immunization prevention and control of RSV infection in China, the Chinese Preventive Medicine Association jointly organized multidisciplinary experts to form a special working group, drawing on the implementation experience of foreign passive immunization prevention of RSV, integrating the existing evidence and the latest progress as a problem oriented, and putting forward the expert consensus on the passive immunization prevention of infant RSV infection in China in the future. The aim is to answer some professional questions about RSV infection and its immunoprophylaxis, especially passive immunoprophylaxis, in order to provide reference for the practice of immunoprophylaxis for professionals in medical institutions, disease prevention and control institutions and community health service centers at all levels.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical features and prognostic factors of AIDS-associated diffuse large B-cell lymphoma]. [艾滋病相关弥漫大 B 细胞淋巴瘤的临床特征和预后因素]。
Q3 Medicine Pub Date : 2024-09-27 DOI: 10.3760/cma.j.cn112150-20240422-00332
W Luo, Q H Ma, L Y He, H C Wang, F L Wu, J W Hu, Y Wu, T Tao
<p><p>To explore the general clinical features and treatment outcomes of patients with AIDS-related diffuse large B-cell lymphoma (AIDS-DLBCL) and provide a theoretical basis for diagnosis and treatment, survival prognosis, prevention and management of AIDS-DLBCL patients. AIDS-DLBCL patients who received combined antiretroviral therapy (cART) at Changsha First Hospital from January 2017 to January 2020 were selected in this study. The survival curves were plotted using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to analyze the association between AIDS-DLBCL specific variables and progression-free survival and overall survival. Correlation analysis was conducted based on the clinical features of the patients. A total of 50 AIDS-DLBCL patients were included. Their median age (<i>Q<sub>1</sub>, Q<sub>3</sub></i>) was 52 (44, 59) years, of whom 46 (92%) were male. About 20 (40%) patients received treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), while 23 patients (46%) received treatment with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Survival curve analysis showed that the 2-year progression-free survival rate and overall survival rate of AIDS-DLBCL patients were 56.9% and 61.6%, respectively. Patients with RCHOP protocol combined with EBV-DNA≥1 000 copies/ml had higher progression-free survival rate (χ<sup>2</sup>=3.844, <i>P</i>=0.043) and overall survival rate (χ<sup>2</sup>=4.662, <i>P</i>=0.031) than those with CHOP protocol combined with EBV-DNA≥1 000 copies/ml. A multivariate analysis showed that male (<i>HR</i>=2.70, 95%<i>CI</i>:1.10-6.80), EB viral load≥1 000 copies/ml (<i>HR</i>=1.75, 95%<i>CI</i>:1.12-2.84), HIV-RNA≥200 copies/ml (<i>HR</i>=4.64, 95%<i>CI</i>: 1.73-12.15), ECOG PS score of 2 to 4 points (<i>HR</i>=3.54, 95%<i>CI</i>:1.62-7.33), and international prognostic index (IPI) score of 3 to 5 points (<i>HR</i>=5.21, 95%<i>CI</i>:1.39-20.14) were at a higher risk of disease progression. Patients with EB viral load≥1 000 copies/ml (<i>HR</i>=0.07, 95%<i>CI</i>:0.05-0.93) on the RCHOP regimen had a small risk of disease progression. Males (<i>HR</i>=2.87, 95%<i>CI</i>:1.65-9.17), EB viral load≥1 000 copies/ml (<i>HR</i>=1.61, 95%<i>CI</i>:4.02-9.36), HIV-RNA≥200 copies/ml (<i>HR</i>=1.19, 95%<i>CI</i>:1.58-2.74), ECOG PS score of 2 to 4 (<i>HR</i>=6.42, 95%<i>CI</i>:2.55-14.33), IPI score of 3 to 5 points (<i>HR</i>=2.78, 95%<i>CI</i>:1.41-12.96) had a high risk of mortality. Patients with EB viral load≥1 000 copies/ml (<i>HR</i>=0.24, 95%<i>CI</i>:0.64-0.90) on the RCHOP regimen had a low risk of mortality. In summary, males, ECOG physical status score of 2 to 4 points, IPI score of 3 to 5 points, EB viral load≥1 000 copies/ml and HIV viral load≥200 copies/ml are risk factors affecting progression-free survival and overall survival of AIDS-DLBCL patients. RCHOP regimen combined with EB viral load≥1 000 copies/ml
目的 探讨艾滋病相关弥漫大B细胞淋巴瘤(AIDS-DLBCL)患者的一般临床特征和治疗效果,为AIDS-DLBCL患者的诊断治疗、生存预后、预防和管理提供理论依据。本研究选取2017年1月至2020年1月在长沙市第一医院接受联合抗逆转录病毒治疗(cART)的AIDS-DLBCL患者为研究对象。采用Kaplan-Meier法绘制生存曲线,并采用Cox比例危险回归模型分析AIDS-DLBCL特定变量与无进展生存期和总生存期之间的关系。根据患者的临床特征进行了相关性分析。研究共纳入了50名AIDS-DLBCL患者。他们的中位年龄(Q1,Q3)为52(44,59)岁,其中46人(92%)为男性。约20名患者(40%)接受了环磷酰胺、多柔比星、长春新碱和泼尼松(CHOP)治疗,23名患者(46%)接受了利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(RCHOP)治疗。生存曲线分析显示,AIDS-DLBCL 患者的两年无进展生存率和总生存率分别为 56.9% 和 61.6%。RCHOP方案联合EBV-DNA≥1 000拷贝/毫升的患者的无进展生存率(χ2=3.844,P=0.043)和总生存率(χ2=4.662,P=0.031)高于CHOP方案联合EBV-DNA≥1 000拷贝/毫升的患者。多变量分析表明,男性(HR=2.70,95%CI:1.10-6.80)、EB病毒载量≥1 000拷贝/毫升(HR=1.75,95%CI:1.12-2.84)、HIV-RNA≥200拷贝/毫升(HR=4.64,95%CI: 1.73-12.15)、ECOG PS评分≥1 000拷贝/毫升(HR=1.75,95%CI:1.12-2.84)、HIV-RNA≥200拷贝/毫升(HR=4.64,95%CI:1.73-12.15)、ECOG PS 评分 2 至 4 分(HR=3.54,95%CI:1.62-7.33)和国际预后指数(IPI)评分 3 至 5 分(HR=5.21,95%CI:1.39-20.14)的患者疾病进展风险较高。EB病毒载量≥1000拷贝/毫升(HR=0.07,95%CI:0.05-0.93)的患者接受RCHOP方案治疗后,疾病进展的风险较小。男性(HR=2.87,95%CI:1.65-9.17)、EB病毒载量≥1 000拷贝/毫升(HR=1.61,95%CI:4.02-9.36)、HIV-RNA≥200拷贝/毫升(HR=1.19,95%CI:1.58-2.74)、ECOG PS 评分 2 至 4 分(HR=6.42,95%CI:2.55-14.33)、IPI 评分 3 至 5 分(HR=2.78,95%CI:1.41-12.96)的患者有较高的死亡风险。EB病毒载量≥1 000拷贝/毫升(HR=0.24,95%CI:0.64-0.90)的患者采用RCHOP方案的死亡风险较低。综上所述,男性、ECOG体力状态评分2至4分、IPI评分3至5分、EB病毒载量≥1 000拷贝/毫升和HIV病毒载量≥200拷贝/毫升是影响艾滋病-DLBCL患者无进展生存期和总生存期的危险因素。RCHOP方案联合EB病毒载量≥1000拷贝/毫升是影响艾滋病-DLBCL患者无进展生存期和总生存期的保护因素。
{"title":"[Clinical features and prognostic factors of AIDS-associated diffuse large B-cell lymphoma].","authors":"W Luo, Q H Ma, L Y He, H C Wang, F L Wu, J W Hu, Y Wu, T Tao","doi":"10.3760/cma.j.cn112150-20240422-00332","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240422-00332","url":null,"abstract":"&lt;p&gt;&lt;p&gt;To explore the general clinical features and treatment outcomes of patients with AIDS-related diffuse large B-cell lymphoma (AIDS-DLBCL) and provide a theoretical basis for diagnosis and treatment, survival prognosis, prevention and management of AIDS-DLBCL patients. AIDS-DLBCL patients who received combined antiretroviral therapy (cART) at Changsha First Hospital from January 2017 to January 2020 were selected in this study. The survival curves were plotted using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to analyze the association between AIDS-DLBCL specific variables and progression-free survival and overall survival. Correlation analysis was conducted based on the clinical features of the patients. A total of 50 AIDS-DLBCL patients were included. Their median age (&lt;i&gt;Q&lt;sub&gt;1&lt;/sub&gt;, Q&lt;sub&gt;3&lt;/sub&gt;&lt;/i&gt;) was 52 (44, 59) years, of whom 46 (92%) were male. About 20 (40%) patients received treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), while 23 patients (46%) received treatment with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Survival curve analysis showed that the 2-year progression-free survival rate and overall survival rate of AIDS-DLBCL patients were 56.9% and 61.6%, respectively. Patients with RCHOP protocol combined with EBV-DNA≥1 000 copies/ml had higher progression-free survival rate (χ&lt;sup&gt;2&lt;/sup&gt;=3.844, &lt;i&gt;P&lt;/i&gt;=0.043) and overall survival rate (χ&lt;sup&gt;2&lt;/sup&gt;=4.662, &lt;i&gt;P&lt;/i&gt;=0.031) than those with CHOP protocol combined with EBV-DNA≥1 000 copies/ml. A multivariate analysis showed that male (&lt;i&gt;HR&lt;/i&gt;=2.70, 95%&lt;i&gt;CI&lt;/i&gt;:1.10-6.80), EB viral load≥1 000 copies/ml (&lt;i&gt;HR&lt;/i&gt;=1.75, 95%&lt;i&gt;CI&lt;/i&gt;:1.12-2.84), HIV-RNA≥200 copies/ml (&lt;i&gt;HR&lt;/i&gt;=4.64, 95%&lt;i&gt;CI&lt;/i&gt;: 1.73-12.15), ECOG PS score of 2 to 4 points (&lt;i&gt;HR&lt;/i&gt;=3.54, 95%&lt;i&gt;CI&lt;/i&gt;:1.62-7.33), and international prognostic index (IPI) score of 3 to 5 points (&lt;i&gt;HR&lt;/i&gt;=5.21, 95%&lt;i&gt;CI&lt;/i&gt;:1.39-20.14) were at a higher risk of disease progression. Patients with EB viral load≥1 000 copies/ml (&lt;i&gt;HR&lt;/i&gt;=0.07, 95%&lt;i&gt;CI&lt;/i&gt;:0.05-0.93) on the RCHOP regimen had a small risk of disease progression. Males (&lt;i&gt;HR&lt;/i&gt;=2.87, 95%&lt;i&gt;CI&lt;/i&gt;:1.65-9.17), EB viral load≥1 000 copies/ml (&lt;i&gt;HR&lt;/i&gt;=1.61, 95%&lt;i&gt;CI&lt;/i&gt;:4.02-9.36), HIV-RNA≥200 copies/ml (&lt;i&gt;HR&lt;/i&gt;=1.19, 95%&lt;i&gt;CI&lt;/i&gt;:1.58-2.74), ECOG PS score of 2 to 4 (&lt;i&gt;HR&lt;/i&gt;=6.42, 95%&lt;i&gt;CI&lt;/i&gt;:2.55-14.33), IPI score of 3 to 5 points (&lt;i&gt;HR&lt;/i&gt;=2.78, 95%&lt;i&gt;CI&lt;/i&gt;:1.41-12.96) had a high risk of mortality. Patients with EB viral load≥1 000 copies/ml (&lt;i&gt;HR&lt;/i&gt;=0.24, 95%&lt;i&gt;CI&lt;/i&gt;:0.64-0.90) on the RCHOP regimen had a low risk of mortality. In summary, males, ECOG physical status score of 2 to 4 points, IPI score of 3 to 5 points, EB viral load≥1 000 copies/ml and HIV viral load≥200 copies/ml are risk factors affecting progression-free survival and overall survival of AIDS-DLBCL patients. RCHOP regimen combined with EB viral load≥1 000 copies/ml","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Epidemiological characteristics of human respiratory syncytial virus infection in febrile respiratory syndrome cases in China from 2010 to 2020]. [2010-2020年中国发热呼吸综合征病例中人类呼吸道合胞病毒感染的流行病学特征]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20231105-00313
B S Li, Y Shi, M J Geng, Y Q Guo, F Lin, Y P Zhang, Z J Li, L P Wang

Objective: To analyze the epidemiological characteristics of human respiratory syncytial virus (HRSV) in cases of febrile respiratory syndrome in China from 2010 to 2020. Methods: Based on the sub-project of the National Science and Technology Major Project for Infectious Disease Prevention and Control "Infectious Disease Monitoring Technology Platform", active monitoring of febrile respiratory syndrome cases was conducted in sentinel hospitals in 31 provinces across China (excluding Hong Kong, Macau, and Chinese Taiwan) from January 2010 to December 2020, resulting in the inclusion of 191 441 cases. Clinical specimens of monitored cases were screened for HRSV nucleic acid, and the differences in HRSV detection rates among different age groups, regions, and time periods were analyzed using the χ2 test/Fisher exact probability method. Results: Among the 191 441 cases of febrile respiratory syndrome in China from 2010 to 2020, the age group M (Q1, Q3) was 9 (2, 40) years old, with 83 773 cases (43.8%) in the <5 years old group. There were 113 660 males, with a male-to-female ratio of 1.5∶1.0. There were as many as 105 508 cases (55.2%) of scattered children and preschool children. About 70 565 cases (36.9%) lived in the northern region. There were 13 858 HRSV positive cases, with a total positive rate of 7.2%. The positive rate of HRSV detection in the northern population was 5.7% (4 004/70 565), which was lower than that in the southern population (8.2%, 9 854/120 876), and the difference was statistically significant (χ2=407.4, P<0.001). HRSV was detected in all age groups, with the highest positive rate of 23.9% in the <6 months age group. The month with the highest positive rate was December, and autumn and winter were the main epidemic seasons. Both northern and southern HRSV subtypes were mainly infected with type A, with a low proportion of mixed infections of type A and type B. Conclusion: HRSV is a common pathogen causing respiratory infections in children from 2010 to 2020. It can be detected throughout the year and shows the main peak of prevalence in autumn and winter. The HRSV strain is mainly classified as a type A infection.

目的分析 2010-2020 年中国发热呼吸综合征病例中人类呼吸道合胞病毒(HRSV)的流行病学特征。研究方法依托国家传染病防治科技重大专项 "传染病监测技术平台 "子课题,自2010年1月至2020年12月,在全国31个省(不含港、澳、台地区)的哨点医院开展发热呼吸综合征病例主动监测,共纳入病例191 441例。对监测病例的临床标本进行了HRSV核酸筛查,并采用χ2检验/Fisher精确概率法分析了不同年龄组、地区和时间段之间HRSV检出率的差异。结果:2010-2020年中国191 441例发热呼吸综合征病例中,年龄组M(Q1,Q3)为9(2,40)岁,其中年龄组M为83 773例(43.8%)2=407.4,PC结论:从 2010 年到 2020 年,HRSV 是导致儿童呼吸道感染的常见病原体。该病毒一年四季均可检出,秋冬季为主要流行高峰。HRSV 株主要分为 A 型感染。
{"title":"[Epidemiological characteristics of human respiratory syncytial virus infection in febrile respiratory syndrome cases in China from 2010 to 2020].","authors":"B S Li, Y Shi, M J Geng, Y Q Guo, F Lin, Y P Zhang, Z J Li, L P Wang","doi":"10.3760/cma.j.cn112150-20231105-00313","DOIUrl":"10.3760/cma.j.cn112150-20231105-00313","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the epidemiological characteristics of human respiratory syncytial virus (HRSV) in cases of febrile respiratory syndrome in China from 2010 to 2020. <b>Methods:</b> Based on the sub-project of the National Science and Technology Major Project for Infectious Disease Prevention and Control \"Infectious Disease Monitoring Technology Platform\", active monitoring of febrile respiratory syndrome cases was conducted in sentinel hospitals in 31 provinces across China (excluding Hong Kong, Macau, and Chinese Taiwan) from January 2010 to December 2020, resulting in the inclusion of 191 441 cases. Clinical specimens of monitored cases were screened for HRSV nucleic acid, and the differences in HRSV detection rates among different age groups, regions, and time periods were analyzed using the χ<sup>2</sup> test/Fisher exact probability method. <b>Results:</b> Among the 191 441 cases of febrile respiratory syndrome in China from 2010 to 2020, the age group <i>M</i> (<i>Q</i><sub>1</sub>, <i>Q</i><sub>3</sub>) was 9 (2, 40) years old, with 83 773 cases (43.8%) in the <5 years old group. There were 113 660 males, with a male-to-female ratio of 1.5∶1.0. There were as many as 105 508 cases (55.2%) of scattered children and preschool children. About 70 565 cases (36.9%) lived in the northern region. There were 13 858 HRSV positive cases, with a total positive rate of 7.2%. The positive rate of HRSV detection in the northern population was 5.7% (4 004/70 565), which was lower than that in the southern population (8.2%, 9 854/120 876), and the difference was statistically significant (χ<sup>2</sup>=407.4, <i>P</i><0.001). HRSV was detected in all age groups, with the highest positive rate of 23.9% in the <6 months age group. The month with the highest positive rate was December, and autumn and winter were the main epidemic seasons. Both northern and southern HRSV subtypes were mainly infected with type A, with a low proportion of mixed infections of type A and type B. <b>Conclusion:</b> HRSV is a common pathogen causing respiratory infections in children from 2010 to 2020. It can be detected throughout the year and shows the main peak of prevalence in autumn and winter. The HRSV strain is mainly classified as a type A infection.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Progress in the study of the correlation between dyslipidemia and demyelinating diseases of the nervous system]. [血脂异常与神经系统脱髓鞘疾病相关性的研究进展]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20240110-00042
X Li, L J Wang, G J Zhang

Demyelinating disorders of the nervous system constitute a broad spectrum of neurological conditions characterized by the depletion of myelin sheaths accompanied by inflammatory cell infiltration, manifesting in either the central or peripheral nervous system. The former primarily encompasses conditions such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), while the latter is exemplified predominantly by Guillain-Barre syndrome (GBS). Recent investigations have revealed that dyslipidemia may be related to the occurrence and development of neurological demyelination, but there are fewer analyses and summaries of related advances in China. Consequently, this review aims to comprehensively outline advancements in research concerning the correlation between dyslipidemia and neurological demyelinating disordersand discusses in depth the interrelationship between dyslipidemia and neurological demyelinating diseases, so as to provide reference for the prevention and treatment of neurological demyelinating diseases.

神经系统脱髓鞘疾病是一种范围广泛的神经系统疾病,其特征是髓鞘耗竭并伴有炎性细胞浸润,表现为中枢或周围神经系统。前者主要包括多发性硬化症(MS)和神经脊髓炎视网膜频谱病变(NMOSD)等疾病,而后者主要以格林-巴利综合征(GBS)为例。近年来的研究发现,血脂异常可能与神经系统脱髓鞘的发生和发展有关,但国内对相关研究进展的分析和总结较少。因此,本综述旨在全面概述血脂异常与神经系统脱髓鞘疾病相关性的研究进展,深入探讨血脂异常与神经系统脱髓鞘疾病的相互关系,为神经系统脱髓鞘疾病的防治提供参考。
{"title":"[Progress in the study of the correlation between dyslipidemia and demyelinating diseases of the nervous system].","authors":"X Li, L J Wang, G J Zhang","doi":"10.3760/cma.j.cn112150-20240110-00042","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240110-00042","url":null,"abstract":"<p><p>Demyelinating disorders of the nervous system constitute a broad spectrum of neurological conditions characterized by the depletion of myelin sheaths accompanied by inflammatory cell infiltration, manifesting in either the central or peripheral nervous system. The former primarily encompasses conditions such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), while the latter is exemplified predominantly by Guillain-Barre syndrome (GBS). Recent investigations have revealed that dyslipidemia may be related to the occurrence and development of neurological demyelination, but there are fewer analyses and summaries of related advances in China. Consequently, this review aims to comprehensively outline advancements in research concerning the correlation between dyslipidemia and neurological demyelinating disordersand discusses in depth the interrelationship between dyslipidemia and neurological demyelinating diseases, so as to provide reference for the prevention and treatment of neurological demyelinating diseases.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Analysis of problems and management of in vitro diagnostic reagent clinical trials in medical laboratory]. [医学实验室体外诊断试剂临床试验问题分析与管理]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20240408-00284
Y H Mao, T R Cao, L H Chen, J W Hu, L Y Zhou, Q H Ma, X Y Song, K Yuan

Clinical trials are an important method for evaluating the safety and efficacy of in vitro diagnostic reagents, and are a key basis for product registration review and approval. In order to strengthen the management of clinical trials of in vitro diagnostic reagents, the National Medical Products Administration and relevant departments have formulated a series of regulations at the regulatory level, and require applicants and clinical trial institutions to establish a quality management system for clinical trials of in vitro diagnostic reagents. Medical laboratory is the main department and implementer of in vitro diagnostic reagent clinical trials in medical institutions. In recent years, with the rapid development of the in vitro diagnostic industry, the clinical trial projects of in vitro diagnostic reagents conducted by medical laboratory have been increasing day by day. However, there are currently few discussions on the clinical trial of in vitro diagnostic reagents from the perspective of researchers. Therefore, this article summarizes the characteristics of clinical trials of in vitro diagnostic reagents, analyzes the problems and difficulties in conducting clinical trials of in vitro diagnostic reagents in current medical laboratories, and introduces the laboratory's experience in management; to provide reference for medical testing laboratories that have not yet conducted or have already conducted clinical trials of in vitro diagnostic reagents, in order to improve the quality and efficiency of clinical trials.

临床试验是评价体外诊断试剂安全性和有效性的重要方法,是产品注册审评审批的重要依据。为加强体外诊断试剂临床试验的管理,国家医药产品管理局及相关部门从法规层面制定了一系列规定,要求申请者和临床试验机构建立体外诊断试剂临床试验质量管理体系。医学检验科是医疗机构体外诊断试剂临床试验的主要部门和实施者。近年来,随着体外诊断行业的快速发展,医学实验室开展的体外诊断试剂临床试验项目与日俱增。然而,目前从研究者角度对体外诊断试剂临床试验的讨论却很少。因此,本文总结了体外诊断试剂临床试验的特点,分析了当前医学实验室开展体外诊断试剂临床试验存在的问题和困难,介绍了实验室在管理方面的经验;为尚未开展或已开展体外诊断试剂临床试验的医学检验实验室提供参考,以提高临床试验的质量和效率。
{"title":"[Analysis of problems and management of <i>in vitro</i> diagnostic reagent clinical trials in medical laboratory].","authors":"Y H Mao, T R Cao, L H Chen, J W Hu, L Y Zhou, Q H Ma, X Y Song, K Yuan","doi":"10.3760/cma.j.cn112150-20240408-00284","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240408-00284","url":null,"abstract":"<p><p>Clinical trials are an important method for evaluating the safety and efficacy of <i>in vitro</i> diagnostic reagents, and are a key basis for product registration review and approval. In order to strengthen the management of clinical trials of <i>in vitro</i> diagnostic reagents, the National Medical Products Administration and relevant departments have formulated a series of regulations at the regulatory level, and require applicants and clinical trial institutions to establish a quality management system for clinical trials of <i>in vitro</i> diagnostic reagents. Medical laboratory is the main department and implementer of <i>in vitro</i> diagnostic reagent clinical trials in medical institutions. In recent years, with the rapid development of the <i>in vitro</i> diagnostic industry, the clinical trial projects of <i>in vitro</i> diagnostic reagents conducted by medical laboratory have been increasing day by day. However, there are currently few discussions on the clinical trial of <i>in vitro</i> diagnostic reagents from the perspective of researchers. Therefore, this article summarizes the characteristics of clinical trials of <i>in vitro</i> diagnostic reagents, analyzes the problems and difficulties in conducting clinical trials of <i>in vitro</i> diagnostic reagents in current medical laboratories, and introduces the laboratory's experience in management; to provide reference for medical testing laboratories that have not yet conducted or have already conducted clinical trials of <i>in vitro</i> diagnostic reagents, in order to improve the quality and efficiency of clinical trials.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Genomic characterization and cluster analysis of Carbapenem-resistant Klebsiella pneumoniae]. [耐碳青霉烯类肺炎克雷伯菌的基因组特征和聚类分析]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20240407-00280
L J Li, Z Y Yuan, L Zhang, R T Deng, L S Lai, W C Huang, W J Fu

To investigate the genomic features and perform cluster analysis of Carbapenem-resistant Klebsiella pneumoniae (CRKP) to provide an experimental basis for guiding the prevention and treatment of CRKP infections.A retrospective case-cohort study was conducted on 19 non-redundant CRKP strains isolated from the Tenth Affiliated Hospital of Southern Medical University between January and June 2023. Whole genome sequencing (WGS) and multilocus sequence typing (MLST) were performed to compare genomic features and analyze the resistance genes and homology of the strains.The results showed that the 19 CRKP strains were isolated from 8 different clinical departments, mainly from respiratory specimens. The whole genome sequencing revealed that the genomic lengths of CRKP ranged from 4.90 to 5.85 Mbp, with contigs N50 values>20 kb for each genome. The median overall GC content was 57.0% (50.4%-57.1%). Comparative genomic analysis identified three regions with high genomic variability. WGS detected 32 resistance genes across 11 categories. All 19 strains carried carbapenem resistance genes (blaKPC-2 and blaOXA-48), blaTEM-1B extended-spectrum β-lactamase resistance genes, qnrS1 quinolone resistance gene, and fosA fosfomycin resistance gene, with each strain carrying only one carbapenemase gene. The detection rate of blaKPC-2 was 94.7% (18/19). MLST identified three sequence types: ST11, ST437 and ST147, with ST11 being predominant (89.5%, 17/19). Clustering analysis based on acquired resistance genes revealed three clonal transmission patterns among strains 72 and 90, and strains 88, 84, 66 and 79.In conclusion, CRKP strains carry multiple resistance genes, and clustering analysis indicating that nosocomial clonal transmission is closely related to acquired resistance genes. The ST11-blaKPC-2 type strain is the predominant clone. Strengthened surveillance and effective control strategies are necessary to reduce nosocomial transmission of CRKP.

研究耐碳青霉烯类肺炎克雷伯菌(CRKP)的基因组特征并进行聚类分析,为指导CRKP感染的预防和治疗提供实验依据。研究人员对2023年1月至6月期间从南方医科大学附属第十医院分离的19株非冗余CRKP菌株进行了回顾性病例队列研究。结果显示,19株CRKP分离自8个不同的临床科室,主要来自呼吸道标本。全基因组测序结果显示,CRKP的基因组长度在4.90至5.85 Mbp之间,每个基因组的等位基因N50值均大于20 kb。总体 GC 含量的中位数为 57.0%(50.4%-57.1%)。比较基因组分析发现了三个基因组变异性较高的区域。WGS 在 11 个类别中检测到 32 个耐药基因。所有 19 株菌株均携带碳青霉烯耐药基因(blaKPC-2 和 blaOXA-48)、blaTEM-1B 广谱 β-内酰胺酶耐药基因、qnrS1 喹诺酮耐药基因和 fosA 磷霉素耐药基因,每株菌株仅携带一个碳青霉烯酶类基因。blaKPC-2 的检出率为 94.7%(18/19)。MLST 鉴定出三种序列类型:ST11、ST437 和 ST147,其中以 ST11 为主(89.5%,17/19)。基于获得性耐药基因的聚类分析显示,在菌株 72 和 90,以及菌株 88、84、66 和 79 之间存在三种克隆传播模式。ST11-blaKPC-2型菌株是最主要的克隆。要减少 CRKP 的院内传播,必须加强监测和采取有效的控制策略。
{"title":"[Genomic characterization and cluster analysis of Carbapenem-resistant <i>Klebsiella pneumoniae</i>].","authors":"L J Li, Z Y Yuan, L Zhang, R T Deng, L S Lai, W C Huang, W J Fu","doi":"10.3760/cma.j.cn112150-20240407-00280","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240407-00280","url":null,"abstract":"<p><p>To investigate the genomic features and perform cluster analysis of Carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP) to provide an experimental basis for guiding the prevention and treatment of CRKP infections.A retrospective case-cohort study was conducted on 19 non-redundant CRKP strains isolated from the Tenth Affiliated Hospital of Southern Medical University between January and June 2023. Whole genome sequencing (WGS) and multilocus sequence typing (MLST) were performed to compare genomic features and analyze the resistance genes and homology of the strains.The results showed that the 19 CRKP strains were isolated from 8 different clinical departments, mainly from respiratory specimens. The whole genome sequencing revealed that the genomic lengths of CRKP ranged from 4.90 to 5.85 Mbp, with contigs N50 values>20 kb for each genome. The median overall GC content was 57.0% (50.4%-57.1%). Comparative genomic analysis identified three regions with high genomic variability. WGS detected 32 resistance genes across 11 categories. All 19 strains carried carbapenem resistance genes (<i>bla</i><sub>KPC-2</sub> and <i>bla</i><sub>OXA-48</sub>), <i>bla</i><sub>TEM-1B</sub> extended-spectrum β-lactamase resistance genes, <i>qnrS1</i> quinolone resistance gene, and <i>fosA</i> fosfomycin resistance gene, with each strain carrying only one carbapenemase gene. The detection rate of <i>bla</i><sub>KPC-2</sub> was 94.7% (18/19). MLST identified three sequence types: ST11, ST437 and ST147, with ST11 being predominant (89.5%, 17/19). Clustering analysis based on acquired resistance genes revealed three clonal transmission patterns among strains 72 and 90, and strains 88, 84, 66 and 79.In conclusion, CRKP strains carry multiple resistance genes, and clustering analysis indicating that nosocomial clonal transmission is closely related to acquired resistance genes. The ST11-<i>bla</i><sub>KPC-2</sub> type strain is the predominant clone. Strengthened surveillance and effective control strategies are necessary to reduce nosocomial transmission of CRKP.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress of lipid-derived parameters in atherosclerotic cardiovascular disease]. [动脉粥样硬化性心血管疾病中脂质衍生参数的研究进展]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20240304-00183
S Z Huang, M Y Yu

Dyslipidemia stands as an autonomous peril in the realm of atherosclerotic cardiovascular maladies. Prompt identification and timely intervention in the case of dyslipidemia hold promise for substantially curbing the onset and fatality rates associated with coronary heart disease. Traditional lipid surveillance metrics employed in clinical settings, such as low-density lipoprotein cholesterol, exhibit notable limitations. Conversely, lipid-derived parameters emerge as formidable contenders, demonstrating a capacity to amalgamate and quantify disparate risk factors and multifactorial etiologies inherent in a given disease. By encompassing a broader spectrum of information than singular indices, these parameters offer a more profound insight into disease progression by virtue of their grounding in the physiological intricacies of lipid metabolism. Drawing upon extant domestic and international guidelines and research, this discourse delineates and synthesizes four lipid-derived parameters with promising clinical applications: atherogenic index of plasma, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, apolipoprotein B/A1 ratio, and lipoprotein combine index, and forwards a perspective grounded in current strides in clinical research.

血脂异常是动脉粥样硬化性心血管疾病中的一个独立危险因素。及时发现和干预血脂异常有望大幅降低冠心病的发病率和死亡率。临床上使用的传统血脂监测指标,如低密度脂蛋白胆固醇,具有明显的局限性。与此相反,血脂衍生参数却成为了强有力的竞争者,显示出了综合和量化特定疾病固有的不同风险因素和多因素病因的能力。与单一指数相比,这些参数涵盖了更广泛的信息,以错综复杂的脂质代谢生理过程为基础,能更深刻地洞察疾病的进展。借鉴国内外现有的指南和研究,本论述划分并综合了四个具有临床应用前景的脂质衍生参数:血浆动脉粥样硬化指数、非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值、载脂蛋白 B/A1 比值和脂蛋白结合指数,并根据当前临床研究的进展提出了自己的观点。
{"title":"[Research progress of lipid-derived parameters in atherosclerotic cardiovascular disease].","authors":"S Z Huang, M Y Yu","doi":"10.3760/cma.j.cn112150-20240304-00183","DOIUrl":"10.3760/cma.j.cn112150-20240304-00183","url":null,"abstract":"<p><p>Dyslipidemia stands as an autonomous peril in the realm of atherosclerotic cardiovascular maladies. Prompt identification and timely intervention in the case of dyslipidemia hold promise for substantially curbing the onset and fatality rates associated with coronary heart disease. Traditional lipid surveillance metrics employed in clinical settings, such as low-density lipoprotein cholesterol, exhibit notable limitations. Conversely, lipid-derived parameters emerge as formidable contenders, demonstrating a capacity to amalgamate and quantify disparate risk factors and multifactorial etiologies inherent in a given disease. By encompassing a broader spectrum of information than singular indices, these parameters offer a more profound insight into disease progression by virtue of their grounding in the physiological intricacies of lipid metabolism. Drawing upon extant domestic and international guidelines and research, this discourse delineates and synthesizes four lipid-derived parameters with promising clinical applications: atherogenic index of plasma, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, apolipoprotein B/A1 ratio, and lipoprotein combine index, and forwards a perspective grounded in current strides in clinical research.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effects of retinopathy on visual function in type 2 diabetes mellitus]. [视网膜病变对 2 型糖尿病患者视觉功能的影响]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20240417-00316
T L Zhang, Z L Hu, H Q Wang, F X Zhao, Q Y Pan, Q Q Zhan, Q Y An, F Y Zhang, T Liu, Y D Hu

Objective: To study the influence of the severity of diabetic retinopathy (DR) on the visual function of patients with type 2 diabetes, to provide scientific basis for the early prevention and control of DR. Methods: This study was designed as a cross-sectional study, recruiting already-diagnosed type 2 diabetes patients in four community health service centers in Guizhou Province between February and September 2022. Employing the Chinese version of the Visual Function Index-14 (VF-14), assess the participants' near vision, visual adaptation, subjective visual perception, and stereo vision, with higher scores indicating poorer visual function. Categorize the severity of each eye's damage into no diabetic retinopathy (DR), mild non-proliferative diabetic retinopathy (NPDR), moderate NPDR, severe NPDR, and proliferative diabetic retinopathy (PDR), and use a 5-level DR grading system to evaluate the overall severity of diabetic retinopathy in both eyes. Employing linear regression analysis to investigate the linear relationship between DR and visual function index. Local weighted regression evaluates the nonlinear relationship between the DR composite score and the scores of visual function, with a steeper slope indicating poorer visual function for that level. Results: A total of 542 patients with type 2 diabetes were investigated, including 244 (45.02%) males, 298 (54.98%) females, and 162 (29.89%) patients with DR. After adjusting for confounders, compared with those without DR, patients with binocular DR Had overall scores (β=0.136, P=0.003), near vision (β=0.163, P<0.001), visual adaptation (β=0.092, P=0.042), subjective vision (β=0.120, P=0.009) and stereo vision (β=0.094, P=0.044) were higher than those without DR. There were no differences in visual functions between DR And monocular DR. The local weighted regression curve showed that near vision (slope: 23.78) and overall score (slope: 58.37) increased sharply from mild to moderate NPDR in both eyes. Visual adaptation (slope: 5.37, 7.72), subjective vision (slope: 6.53, 7.93), stereovision (slope: 0.74, 0.91) increased slowly in mild to moderate NPDR in both eyes and in moderate to severe NPDR/PDR in both eyes. Conclusion: Binocular DR is associated with impaired visual function, but there is no difference between monocular DR And non-DR visual function. The early damage of DR To visual function is mainly manifested in near vision. In the prevention and control of DR, more attention should be paid to visual function, especially the change of near vision, and retinal damage should not be assessed solely by visual status.

研究目的研究糖尿病视网膜病变(DR)的严重程度对 2 型糖尿病患者视功能的影响,为早期预防和控制 DR 提供科学依据。研究方法本研究为横断面研究,于2022年2月至9月在贵州省4个社区卫生服务中心招募已确诊的2型糖尿病患者。采用中文版视功能指数-14(VF-14),评估参与者的近视力、视适应、主观视知觉和立体视觉,得分越高表示视功能越差。将每只眼睛的损伤程度分为无糖尿病视网膜病变(DR)、轻度非增殖性糖尿病视网膜病变(NPDR)、中度非增殖性糖尿病视网膜病变(NPDR)、重度非增殖性糖尿病视网膜病变(NPDR)和增殖性糖尿病视网膜病变(PDR),并使用五级DR分级系统评估双眼糖尿病视网膜病变的总体严重程度。采用线性回归分析研究 DR 与视觉功能指数之间的线性关系。局部加权回归评估 DR 综合评分与视觉功能评分之间的非线性关系,斜率越陡,表明该级别的视觉功能越差。研究结果共调查了 542 名 2 型糖尿病患者,其中男性 244 人(45.02%),女性 298 人(54.98%),DR 患者 162 人(29.89%)。在对混杂因素进行调整后,与非 DR 患者相比,双眼 DR 患者的总分(β=0.136,P=0.003)、近视力(β=0.163,Pβ=0.092,P=0.042)、主观视力(β=0.120,P=0.009)和立体视力(β=0.094,P=0.044)均高于非 DR 患者。DR和单眼DR在视觉功能上没有差异。局部加权回归曲线显示,双眼的近视力(斜率:23.78)和总分(斜率:58.37)从轻度NPDR急剧上升到中度NPDR。双眼视适应(斜率:5.37,7.72)、主观视力(斜率:6.53,7.93)和立体视觉(斜率:0.74,0.91)在轻度至中度 NPDR 和中度至重度 NPDR/PDR 中增长缓慢。结论双眼 DR 与视功能受损有关,但单眼 DR 和非 DR 的视功能没有差异。DR 对视功能的早期损害主要表现在近距离视力上。在预防和控制 DR 的过程中,应更多地关注视功能,尤其是近视力的变化,而不应仅仅通过视力状况来评估视网膜损伤。
{"title":"[Effects of retinopathy on visual function in type 2 diabetes mellitus].","authors":"T L Zhang, Z L Hu, H Q Wang, F X Zhao, Q Y Pan, Q Q Zhan, Q Y An, F Y Zhang, T Liu, Y D Hu","doi":"10.3760/cma.j.cn112150-20240417-00316","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20240417-00316","url":null,"abstract":"<p><p><b>Objective:</b> To study the influence of the severity of diabetic retinopathy (DR) on the visual function of patients with type 2 diabetes, to provide scientific basis for the early prevention and control of DR. <b>Methods:</b> This study was designed as a cross-sectional study, recruiting already-diagnosed type 2 diabetes patients in four community health service centers in Guizhou Province between February and September 2022. Employing the Chinese version of the Visual Function Index-14 (VF-14), assess the participants' near vision, visual adaptation, subjective visual perception, and stereo vision, with higher scores indicating poorer visual function. Categorize the severity of each eye's damage into no diabetic retinopathy (DR), mild non-proliferative diabetic retinopathy (NPDR), moderate NPDR, severe NPDR, and proliferative diabetic retinopathy (PDR), and use a 5-level DR grading system to evaluate the overall severity of diabetic retinopathy in both eyes. Employing linear regression analysis to investigate the linear relationship between DR and visual function index. Local weighted regression evaluates the nonlinear relationship between the DR composite score and the scores of visual function, with a steeper slope indicating poorer visual function for that level. <b>Results:</b> A total of 542 patients with type 2 diabetes were investigated, including 244 (45.02%) males, 298 (54.98%) females, and 162 (29.89%) patients with DR. After adjusting for confounders, compared with those without DR, patients with binocular DR Had overall scores (<i>β</i>=0.136, <i>P=</i>0.003), near vision (<i>β</i>=0.163, <i>P</i><0.001), visual adaptation (<i>β</i>=0.092, <i>P=</i>0.042), subjective vision (<i>β</i>=0.120, <i>P=</i>0.009) and stereo vision (<i>β</i>=0.094, <i>P=</i>0.044) were higher than those without DR. There were no differences in visual functions between DR And monocular DR. The local weighted regression curve showed that near vision (slope: 23.78) and overall score (slope: 58.37) increased sharply from mild to moderate NPDR in both eyes. Visual adaptation (slope: 5.37, 7.72), subjective vision (slope: 6.53, 7.93), stereovision (slope: 0.74, 0.91) increased slowly in mild to moderate NPDR in both eyes and in moderate to severe NPDR/PDR in both eyes. <b>Conclusion:</b> Binocular DR is associated with impaired visual function, but there is no difference between monocular DR And non-DR visual function. The early damage of DR To visual function is mainly manifested in near vision. In the prevention and control of DR, more attention should be paid to visual function, especially the change of near vision, and retinal damage should not be assessed solely by visual status.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Current research status of virus-like particle vaccine]. [病毒样颗粒疫苗的研究现状]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20231123-00366
L Zhang, Y F Yang, X Ma, Y F Zhang, Y Wang

Virus-like particles (VLPs) are self-assembled protein nanoparticles with repetitive antigen epitopes, which can stimulate immune response and do not contain viral genetic materials. VLPs has important research value and application potential in vaccine development, targeted drug delivery and bioengineering materials. In this review, the mechanism of VLPs vaccine induced immune responses is discussed. The existing VLPs expression systems are summarized. The research progress of VLPs vaccine in prevention and treatment of virus infection are summarized. This review provides general reference and guidance for the design and development of antiviral VLPs vaccine.

病毒样颗粒(VLPs)是一种具有重复抗原表位的自组装蛋白纳米颗粒,可激发免疫反应,不含病毒遗传物质。VLPs 在疫苗开发、靶向给药和生物工程材料等方面具有重要的研究价值和应用潜力。本综述讨论了 VLPs 疫苗诱导免疫反应的机制。总结了现有的 VLPs 表达系统。总结了 VLPs 疫苗在预防和治疗病毒感染方面的研究进展。本综述为设计和开发抗病毒 VLPs 疫苗提供了一般参考和指导。
{"title":"[Current research status of virus-like particle vaccine].","authors":"L Zhang, Y F Yang, X Ma, Y F Zhang, Y Wang","doi":"10.3760/cma.j.cn112150-20231123-00366","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20231123-00366","url":null,"abstract":"<p><p>Virus-like particles (VLPs) are self-assembled protein nanoparticles with repetitive antigen epitopes, which can stimulate immune response and do not contain viral genetic materials. VLPs has important research value and application potential in vaccine development, targeted drug delivery and bioengineering materials. In this review, the mechanism of VLPs vaccine induced immune responses is discussed. The existing VLPs expression systems are summarized. The research progress of VLPs vaccine in prevention and treatment of virus infection are summarized. This review provides general reference and guidance for the design and development of antiviral VLPs vaccine.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prenatal screening and prenatal diagnosis clinical laboratory diagnostic pathway]. [产前筛查和产前诊断临床实验室诊断路径]。
Q3 Medicine Pub Date : 2024-09-06 DOI: 10.3760/cma.j.cn112150-20231130-00388
B Qiao, K B Zhu, Z G Wu, J W Wang, H Y Zheng, Y Q Tong

Congenital defects and genetic diseases in the fetus are the focus of prenatal screening and prenatal diagnosis. Obstetrics and gynecology, pediatrics, medical imaging (ultrasound and magnetic resonance imaging), clinical laboratory, pathology, and other disciplines are mostly involved in this multidisciplinary work on maternal and infant health care, which aims to prevent birth defects in strict accordance with laws, regulations, and pertinent industry standards, such as the Notice of the National Health Commission on Issuing the Basic Standards for Prenatal Screening Technical Medical Institutions and the Basic Standards for Prenatal Diagnosis Technical Medical Institutions (Guowei Maternal and Child Letter [2019] No. 297). To further support the implementation of prenatal screening and diagnosis work and streamline workflow, this study has compiled the timing, inspection, and testing procedures of various projects in each link from the standpoint of the disease clinical laboratory diagnostic pathway. This approach improves communication amongst various disciplines in prenatal screening and diagnosis work and offers clinical service quality, and it also helps improve the standard of the birth population and prevent and controll severe birth defects.

胎儿先天缺陷和遗传疾病是产前筛查和产前诊断的重点。妇产科、儿科、医学影像(超声、磁共振)、临床检验科、病理科等多学科共同参与母婴保健工作,严格依法预防出生缺陷、国家卫生健康委员会关于印发产前筛查技术医疗机构基本标准和产前诊断技术医疗机构基本标准的通知》(国卫妇幼函[2019]297号)等法律法规和相关行业标准。297).为进一步支持产前筛查与诊断工作的开展,理顺工作流程,本研究从疾病临床实验室诊断路径的角度出发,梳理了各环节各项目开展的时间、检查、检验流程。这种做法既加强了产前筛查与诊断工作中各学科之间的沟通,提高了临床服务质量,又有助于提高出生人口的水平,预防和控制严重出生缺陷的发生。
{"title":"[Prenatal screening and prenatal diagnosis clinical laboratory diagnostic pathway].","authors":"B Qiao, K B Zhu, Z G Wu, J W Wang, H Y Zheng, Y Q Tong","doi":"10.3760/cma.j.cn112150-20231130-00388","DOIUrl":"https://doi.org/10.3760/cma.j.cn112150-20231130-00388","url":null,"abstract":"<p><p>Congenital defects and genetic diseases in the fetus are the focus of prenatal screening and prenatal diagnosis. Obstetrics and gynecology, pediatrics, medical imaging (ultrasound and magnetic resonance imaging), clinical laboratory, pathology, and other disciplines are mostly involved in this multidisciplinary work on maternal and infant health care, which aims to prevent birth defects in strict accordance with laws, regulations, and pertinent industry standards, such as the Notice of the National Health Commission on Issuing the Basic Standards for Prenatal Screening Technical Medical Institutions and the Basic Standards for Prenatal Diagnosis Technical Medical Institutions (Guowei Maternal and Child Letter [2019] No. 297). To further support the implementation of prenatal screening and diagnosis work and streamline workflow, this study has compiled the timing, inspection, and testing procedures of various projects in each link from the standpoint of the disease clinical laboratory diagnostic pathway. This approach improves communication amongst various disciplines in prenatal screening and diagnosis work and offers clinical service quality, and it also helps improve the standard of the birth population and prevent and controll severe birth defects.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华预防医学杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1